FcRn Inhibitor Market Projected for Robust Growth Through 2036 Across 7MM, Reports DelveInsight

DelveInsight's "FcRn Inhibitors Market Forecast, Target Population, and Competitive Landscape - 2036" report delivers an in-depth understanding of FcRn inhibitors, historical and forecasted competitive landscape, as well as the FcRn inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the FcRn Inhibitor market outlook, drug uptake, treatment scenario, and competitive landscape, Click here: FcRn Inhibitor Market Forecast https://www.delveinsight.com/report-store/fcrn-inhibitor-competitive-landscape-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the FcRn Inhibitor Market Report:
• The FcRn Inhibitors market in the 7MM is projected to grow at a significant CAGR through 2036 across the US, EU4, UK, and Japan.
• In 2025, the FcRn inhibitors market in the US was valued at approximately USD 2.2 billion, and is projected to grow at a robust CAGR over the forecast period (2026-2036).
• By 2036, VYVGART HYTRULO is anticipated to lead the market, capturing an estimated 30% share, reflecting its strong clinical profile and early market entry advantage.
• In March 2026, Johnson & Johnson announced that the FDA had granted Fast Track status to nipocalimab for the potential treatment of adult patients with systemic lupus erythematosus (SLE).
• In February 2026, argenx SE announced encouraging topline results from its Phase 3 ADAPT OCULUS study investigating VYVGART for adults diagnosed with ocular myasthenia gravis.
• In January 2026, argenx SE announced that the FDA had granted priority review to a supplemental BLA for VYVGART, seeking approval for use in adults with AChR antibody seronegative generalized myasthenia gravis (gMG).
• In December 2025, Johnson & Johnson announced that the European Commission granted Marketing Authorisation for IMAAVY (nipocalimab) as an add-on therapy for gMG in adults and adolescents aged 12 and older who are anti-AChR or anti-MuSK antibody-positive.
• In April 2025, the FDA approved IMAAVY (nipocalimab-aahu) by Johnson & Johnson the first FcRn blocker approved for generalized myasthenia gravis in anti-AChR or anti-MuSK antibody-positive adults and pediatric patients aged 12 and older, based on data from the Vivacity-MG3 and Vibrance trials.
• In 2023, global net product revenues for VYVGART and VYVGART SC were USD 908 million and USD 246 million, respectively, reflecting strong established demand.
• Key epidemiology takeaways: chronic inflammatory demyelinating polyneuropathy cases were approximately 21,000 in the US in 2023; Graves' disease had an estimated prevalence of around 1,241,720 cases across EU4 and the UK; and thyroid eye disease cases were approximately 84,000 across the 7MM in 2023.
• The growing focus of major players including argenx, Johnson & Johnson, UCB Biopharma, Immunovant, and Pfizer on expanding FcRn inhibitor indications across gMG, CIDP, Graves' disease, wAIHA, pemphigus vulgaris, SLE, and rheumatoid arthritis is expected to drive continued market expansion.
• Key FcRn Inhibitor Companies: Johnson & Johnson, argenx, Immunovant, UCB Biopharma, Pfizer, Viridian Therapeutics, and others.
• Key FcRn Inhibitor Therapies: VYVGART (efgartigimod), RYSTIGGO (rozanolixizumab-noli), IMAAVY (nipocalimab-aahu), Batoclimab (HBM9161), IMVT-1402, and others.
• The FcRn Inhibitor market is expected to surge due to rising prevalence of IgG-mediated autoimmune diseases, expanding approved indications, and a robust late-stage pipeline entering the market through the forecast period.

FcRn Inhibitors Overview
The neonatal fragment crystallizable (Fc) receptor (FcRn), also known as the Brambell receptor, functions as a recycling mechanism to extend the half-life of IgG and albumin in circulation. FcRn inhibitors are anti-FcRn monoclonal antibodies that compete with IgG for FcRn binding inside cells, preventing IgG from being recycled and directing it toward lysosomal degradation thereby reducing circulating IgG and pathogenic autoantibody levels.
This mechanism offers a targeted, less invasive alternative to plasma exchange (PLEX), immunoadsorption (IA), and high-dose intravenous immunoglobulin (IVIg) therapies. FcRn inhibitors are effective treatments across multiple indications including generalized myasthenia gravis, thyroid eye disease, CIDP, bullous pemphigoid, warm autoimmune hemolytic anemia, and Graves' disease, among others.

Get a Free Sample for the FcRn Inhibitor Market Report https://www.delveinsight.com/report-store/fcrn-inhibitor-competitive-landscape-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

FcRn Inhibitors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted patient pool across the 7MM from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The section provides a detailed analysis of the targeted patient population across selected indications and future trends.

FcRn Inhibitors Epidemiology Segmentation:
The FcRn Inhibitor market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Cases by Indication in the 7MM
• Treatable Cases by Indication in the 7MM
• Total Eligible Patient Pool of Selected Indications for FcRn Inhibitors
• Total Treated Cases in Selected Indications for FcRn Inhibitors

Download the report to understand which factors are driving FcRn Inhibitor patient pool and market trends @ FcRn Inhibitor Epidemiology and Market Forecast https://www.delveinsight.com/report-store/fcrn-inhibitor-competitive-landscape-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

FcRn Inhibitor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of approved and emerging FcRn inhibitors expected to be launched during 2022-2036. The analysis covers market uptake by drug, patient uptake by therapy, and sales of each drug across the 7MM.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal adoption, comparing drugs based on market share. The report also covers FcRn Inhibitor Pipeline Development Activities providing detailed information on collaborations, acquisitions and mergers, licensing, and patent details alongside a clinical trials analysis covering candidates in Phase III, Phase II, and Phase I.

FcRn Inhibitor Therapies and Key Companies
• VYVGART / VYVGART HYTRULO (efgartigimod alfa): argenx - FDA approved for gMG (2021); pipeline in CIDP, TED, myositis, bullous pemphigoid, primary immune thrombocytopenia
• RYSTIGGO (rozanolixizumab-noli): UCB Biopharma - FDA approved for gMG (2023); pipeline in MOGAD, CIDP, fibromyalgia
• IMAAVY (nipocalimab-aahu): Johnson & Johnson - FDA approved for gMG (April 2025); pipeline in FNAIT, CIDP, HDFN, RA, IIM, hemolytic anemia, SLE, lupus nephritis, Sjögren's syndrome
• Batoclimab (HBM9161): Immunovant - Phase III; SC administration; pipeline across gMG, TED, CIDP, Graves' disease
• IMVT-1402: Immunovant - Phase II/III; potential best-in-class anti-FcRn antibody; pipeline across Graves' disease, gMG, CIDP, D2T RA, Sjögren's disease, cutaneous lupus erythematosus

Discover more about therapies set to grab major FcRn Inhibitor market share @ FcRn Inhibitor Treatment Market https://www.delveinsight.com/report-store/fcrn-inhibitor-competitive-landscape-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

FcRn Inhibitor Market Drivers
• Rising prevalence of IgG-mediated autoimmune diseases including gMG, CIDP, thyroid eye disease, and SLE expanding the targeted patient population
• Advancing late-stage pipeline candidates - nipocalimab, batoclimab, and IMVT-1402 - alongside approved drugs diversifying treatment options across multiple indications
• Superior mechanism selectively reducing pathogenic IgG levels without impacting other immunoglobulin classes, offering a safer and more precise alternative to broad immunosuppression
• Improved safety profile versus plasma exchange, IVIg, and other immunomodulators enhancing physician confidence and patient acceptance
• Frequent FDA Breakthrough Therapy, Fast-Track, and EMA designations for pipeline agents shortening development timelines and accelerating market entry
• Successful expansion into CIDP, pemphigus vulgaris, wAIHA, Graves' disease, and RA broadening the therapeutic addressable market
• Active strategic collaborations among argenx, UCB, Immunovant, and Johnson & Johnson fueling R&D, manufacturing scale-up, and global commercialization

FcRn Inhibitor Market Barriers
• High cost of novel biologic therapies creating accessibility and reimbursement challenges across geographies
• Varying reimbursement landscapes across the 7MM, with approval timelines and coverage decisions differing significantly by country
• Patient and physician awareness gaps for newer indications beyond gMG limiting adoption in early treatment settings

Scope of the FcRn Inhibitor Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key FcRn Inhibitor Companies: Johnson & Johnson, argenx, Immunovant, UCB Biopharma, Pfizer, Viridian Therapeutics, and others
• Key FcRn Inhibitor Therapies: VYVGART (efgartigimod), RYSTIGGO (rozanolixizumab), IMAAVY (nipocalimab), Batoclimab, IMVT-1402, and others
• FcRn Inhibitor Therapeutic Assessment: Current marketed and emerging FcRn inhibitor therapies across indications
• FcRn Inhibitor Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, market entry strategies, indication-wise conjoint analysis
• FcRn Inhibitor Unmet Needs, KOL Views, Analyst Views, Market Access, and Reimbursement

Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.